Literature DB >> 2541198

Stimulation of degranulation from human eosinophils by platelet-activating factor.

C Kroegel1, T Yukawa, G Dent, P Venge, K F Chung, P J Barnes.   

Abstract

Platelet-activating factor (PAF) is a highly active mediator which has been implicated in allergic inflammation and bronchial asthma, possibly by interacting with eosinophils. We have examined the effect of PAF on activation of purified human eosinophils as measured by degranulation (eosinophil peroxidase, eosinophil cationic protein, arylsulfatase B, beta-glucuronidase, and alkaline phosphatase) and oxidative metabolism (superoxide anion production). PAF induced enzyme release at concentrations ranging from 1 pM to 10 microM in a rapid (t1/2 5 to 8 min), Ca2+-dependent and noncytotoxic manner from both the specific and small granules, whereas its biologic precursor and metabolite, lyso-PAF, had no effect. For all enzymes, maximal enzyme release occurred at 100 nM PAF with a mean ED50 value of 1.47 +/- 0.4 nM. At this concentration the mean percentage of total enzyme release by PAF from specific granules was 20.3 +/- 1.6% (17.9% for eosinophil peroxidase, 20.6% for beta-glucuronidase, 22.4% for alkaline phosphatase) and 28.8 +/- 2.2% from small granules (arylsulfatase B). Calcium ionophore A23187, PMA, and opsonized zymosan also induced eosinophil degranulation but their peak effect after 10-min incubation with maximal release 14.7%, 12.9%, or 14.1%, respectively, was lower when compared with PAF. Incubation of eosinophils with the PAF-antagonist WEB 2086 led to a parallel shift of the dose-response curve to the right, indicating a competitive antagonism. PAF also caused generation of superoxide anions by human eosinophils but this occurred at higher concentrations of PAF (1 microM to 30 microM) with an ED50 of 8.4 +/- 0.9 microM. Again, this effect was competitively inhibited by WEB 2086. These studies demonstrate that PAF activates human eosinophils to release granule constituents and generate superoxide anions. Since both PAF and eosinophil products are associated with pathogenesis of bronchial asthma our findings may be of particular pathophysiologic relevance.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2541198

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

1.  Adenosine A3 receptors on human eosinophils mediate inhibition of degranulation and superoxide anion release.

Authors:  C I Ezeamuzie; E Philips
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

2.  Cysteine protease secreted by Paragonimus westermani attenuates effector functions of human eosinophils stimulated with immunoglobulin G.

Authors:  M H Shin; H Kita; H Y Park; J Y Seoh
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

Review 3.  The diverse effects of mast cell mediators.

Authors:  Colleen Hines
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

4.  Mouse and human eosinophils degranulate in response to platelet-activating factor (PAF) and lysoPAF via a PAF-receptor-independent mechanism: evidence for a novel receptor.

Authors:  Kimberly D Dyer; Caroline M Percopo; Zhihui Xie; Zhao Yang; John Dongil Kim; Francis Davoine; Paige Lacy; Kirk M Druey; Redwan Moqbel; Helene F Rosenberg
Journal:  J Immunol       Date:  2010-04-26       Impact factor: 5.422

Review 5.  The role of eosinophils in asthma.

Authors:  C Kroegel
Journal:  Lung       Date:  1990       Impact factor: 2.584

6.  Eosinophil granules function extracellularly as receptor-mediated secretory organelles.

Authors:  Josiane S Neves; Sandra A C Perez; Lisa A Spencer; Rossana C N Melo; Lauren Reynolds; Ionita Ghiran; Salahaddin Mahmudi-Azer; Solomon O Odemuyiwa; Ann M Dvorak; Redwan Moqbel; Peter F Weller
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-18       Impact factor: 11.205

7.  Comparative immunoreactivity of the eosinophil constituents MBP and ECP in different types of urticaria.

Authors:  N Haas; K Motel; B M Czarnetzki
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

8.  Priming effect of platelet activating factor on leukotriene C4 from stimulated eosinophils of asthmatic patients.

Authors:  K Shindo; K Koide; Y Hirai; M Sumitomo; M Fukumura
Journal:  Thorax       Date:  1996-02       Impact factor: 9.139

9.  Safety and efficiency of active immunization with detoxified antigen against scorpion venom: side effect evaluation.

Authors:  Nassrine Bachsais; Lila Boussag-Abib; Fatima Laraba-Djebari
Journal:  Inflamm Res       Date:  2017-05-17       Impact factor: 4.575

10.  Enhancement by cyclo-oxygenase inhibitors of platelet-activating factor production in thapsigargin-stimulated macrophages.

Authors:  M Watanabe; M Yamada; S Mue; K Ohuchi
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.